Syed Quadri, MD
Internal Medicine · Elizabethtown, KYNPI 1912916024
Payments from drug & device makers
Across 3 payments — averaging $14.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$20
- Biohaven Pharmaceutical Holding Company Ltd.$16
- Fidia Pharma USA Inc.$8
What the payments were for
- Food & beverage$2454%
- Other$2046%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Fidia Pharma USA Inc. | 1 | $8 |
How this compares
$43 in reported general payments places this provider in the 20th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 143 | $145,208 |
| JardianceEmpagliflozin | 158 | $141,156 |
| EliquisApixaban | 137 | $114,521 |
| MounjaroTirzepatide | 75 | $80,504 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 104 | $79,457 |
| JanuviaSitagliptin Phosphate | 69 | $51,535 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $48,535 |
| Daptomycin | 13 | $43,017 |
| XifaxanRifaximin | 12 | $39,599 |
| LinzessLinaclotide | 53 | $38,903 |
| TrulicityDulaglutide | 22 | $36,346 |
| MyrbetriqMirabegron | 51 | $21,006 |
| FarxigaDapagliflozin Propanediol | 25 | $20,738 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $20,046 |
| TradjentaLinagliptin | 21 | $17,899 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Elizabethtown
- Mark AdamsLondon$15.4M
- Matthew WenkerErlanger$12.8M
- Jason ChesneyLouisville$6.3M
- Neil FarrisLexington$3M
- David JohnsonOwensboro$787K
- Hollis ClarkMurray$780K
- Fares KhaterWhitesburg$412K
- Christopher PhillipsPaducah$315K
- Cynthia Bowman-StroudPaducah$234K
- Bernard BuchananOwensboro$224K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.